Latest / Gladden Longevity Podcast / Navigating the World of 503A and 503B Pharmacies - Episode 355

Transcript

Navigating the World of 503A and 503B Pharmacies - Episode 355 · Gladden Longevity Podcast

0:00
Couple weeks ago, the FDA had a pharmacy compounding committee come together
0:05
and look at eight different peptides.
0:07
Out of the eight, if I'm not mistaken,
0:09
seven of them were approved, or the committee said to the FDA,
0:13
these are ones that we feel need to be added to the 503A bolts list.
0:18
Hey everyone, Dr. Gladden here.
0:20
I just got off a podcast with Joshua and Nicole from Olympia
0:24
and Wesley Pharmacies in ~ Orlando,
0:27
Florida. They're a compounding conglomerate there.
0:29
And it's an interesting podcast because we break down the whole 503A,
0:33
503B compounding, what they can do,
0:36
what they can't do. We get into the whole peptide story about what's happening with
0:39
the FDA, with the peptides that have been suggested for approval
0:43
and things like that. So I think you're gonna find this very interesting
0:46
and clarifying. If you have any questions about compounding.
0:48
pharmacies, this will be a good one to listen to.
0:51
He went from saving hearts as a cardiologist to rewriting the entire aging playbook.
0:56
Dr. Jeffrey Gladden believes 100 is the new 30 and he's got the science
1:01
to back it up. This is the Gladden Longevity Podcast.
1:05
Well, welcome Josh and Nicole to the Glad Longevity Podcast.
1:08
It's good to see you. Glad you're joining us today.
1:10
It should be an interesting conversation here.
1:12
We're gonna talk about compounding pharmacies,
1:14
which I think is a big part of what we do in the regenerative functional medicine
1:18
space, et cetera, longevity medicine space.
1:20
So welcome to the show. Yeah. Thanks for having us.
1:23
So Josh, let's let's start with you.
1:26
You're the CFO of a pharmacy in Florida.
1:29
And you know, there's been a lot of I think confusion
1:33
for people around compounding pharmacies.
1:35
I think people have heard, you know,
1:36
things thrown around 503A, 503B.
1:39
I'm not sure people really understand the difference there.
1:41
I know that probably the what the audience is most familiar with,
1:45
however, is, you know, the use of peptides.
1:47
And people have gotten comfortable using peptides.
1:50
I got certified in peptide use with A4M back in two thousand seventeen with Dr.
1:55
Seats and we started using them back then.
1:58
So they've been around for a long time and we've had a lot of great experience with
2:01
them.
2:02
But there's a lot going on there with the FTA and things like that.
2:04
But let's let's start off with maybe just sort of defining whoever wants
2:10
to jump in on this, you know, what a compounding pharmacy is.
2:13
Why why you came into existence?
2:15
What what was the need? I can
2:17
Can leave this off and Nicole,
2:18
feel free to jump in. Josh Fritzler,
2:20
president of Olympia and Wesley Pharmaceuticals.
2:23
So, just for what we're familiar with,
2:25
Olympia Pharmaceuticals is a 503B.
2:28
We also have Olympia Pharmacy,
2:29
which is a 503A, and then we have Wesley Pharmaceuticals,
2:33
another 503B. That is the umbrella of companies and pharmacies we have.
2:37
So what's a f what's a five three A?
2:39
What's a five three B? Yep, so five three A
2:41
Is more of a community pharmacy that could have ~ compounding in its facility.
2:46
Our facility does sterile 503A compounding for testosterone,
2:50
which is a hazardous compounding,
2:52
and then we do non-sterile. 503A follows USP guidelines set by the state regulators.
2:57
It has specific ways of dispensing.
3:00
You have to dispense with a prescription,
3:01
has to have a patient label before it leaves your facility.
3:04
Or in very layman's terms, a 503B is an outsourcing facility.
3:08
We have larger batch sizes of ten thousand to fifteen thousand vials,
3:12
where a five three A has two hundred and fifty vials per batch.
3:15
So the way the way I understand it is a five three A basically is
3:19
a pharmacy that's making a particular compounded and we'll talk about what
3:24
compounded actually means pharmaceutical for an individual.
3:28
Correct. And a five three B is actually making large quantities
3:32
of a particular compounded thing that can be used otherwise.
3:36
Let's talk about compounding. What is what is it to be what is it
3:39
to be compounding something, Nicole?
3:41
So when you compound something,
3:42
you are actually making something that's not commercially available.
3:47
So for us, we're in the health and wellness.
3:50
So we do a lot of vitamins, minerals,
3:52
things like that. There is sterile,
3:54
which goes through a process that means it's gonna be injected somehow,
3:58
or IV. And then there's non-sterile,
4:00
which is what we see typically in your community pharmacies,
4:03
these your creams, tablets, capsules,
4:05
anything that doesn't actually have to be injected.
4:08
Mm-hmm. So you can make things sterily and non sterily.
4:11
And why would somebody want something compounded?
4:14
Why why would why would somebody want that?
4:16
Great question, because when you get something compounded,
4:19
you can make it directly for that patient.
4:21
Some patients might not be able to handle the doses that are out there from
4:25
a commercial standpoint or some of the fillers that they have if they have
4:29
an intolerance to say lactose or soy,
4:33
or it's just maybe not available commercially,
4:35
the dosing that they need to in order to service them.
4:38
So you're a pharmacy that basically has all of the access to all
4:43
of the medications that somebody would find at Walgreens or C V S.
4:46
And what you can do is you can actually make those in different concentrations
4:51
or different doses or things like that that somebody couldn't just walk into
4:56
C V S and get it off the shelf in the doses that the manufacturer made.
5:00
Correct. Combine certain products.
5:03
So like creams, like putting two to three creams together or ~ solutions that you're
5:08
not gonna find you're right at the local pharmacy.
5:10
Right. So this can be of value to a client because all of a sudden,
5:15
~ maybe there's a hormone combination that they want to have that
5:20
is not available and they know from testing or whatever else that they need this
5:24
amount of estrogen and this amount of progesterone and you know,
5:27
whatever else, testosterone, and all of a sudden they can get that into
5:31
a compounded product that they couldn't find anywhere else.
5:34
Right. So there's there's a convenience element,
5:37
but then there's also kind of a precision.
5:40
element to all this where what you're really doing is getting
5:44
the individual exactly what they need,
5:46
right? Right. In conjunction with these particular drugs,
5:50
one drug or could it be several drugs.
5:52
And that's that's really why compounding pharmacies came into exist existence
5:57
was to meet the need of people that,
5:59
you know, couldn't get along with just the standard dosing.
6:03
Is that how we should understand it?
6:05
Exactly.
6:05
Or the standard products. They needed something that was specifically made
6:10
for them and their condition or what they were looking to treat,
6:14
something like that. And so that's where compounding comes in.
6:17
It offers you that ~ a la carte,
6:20
make it for this patient and get what they truly need.
6:23
need.
6:24
So with the 503A's, they're gonna function.
6:27
If if you haven't ever walked into a compounding pharmacy and you're listening
6:31
to this, if you walk into a five three A,
6:33
it's gonna look kind of like pharmacy.
6:34
I mean you're gonna see, you know,
6:36
shelves with stuff on it and different creams and things like that.
6:40
But then there's a counter where you can actually submit a s prescription from
6:44
a physician and they can make an actual product just for you.
6:48
And again it functions a lot like a regular pharmacy.
6:51
Now it's interesting to note that
6:53
These are not, even though let's say the drug off the shelf is FDA approved,
6:58
the compounded formulation is not FDA approved,
7:02
right? Correct. And it's interesting that it's not approved.
7:05
And the reason the FDA doesn't approve it is I suppose because they can't really
7:09
cover all the different potential,
7:10
you know, combinations and doses and all of that sort of thing,
7:14
right? So it's important to understand that if you're getting something from
7:17
a confounded pharmacy, even though it's an FDA approved drug.
7:21
The form in which you're getting it in and of itself is not FDA approved.
7:24
Yeah.
7:25
Or it's a combination of FDA approved ~ ingredients.
7:29
Correct. That's an interesting thing.
7:31
So from a safety and efficacy standpoint,
7:34
I can tell you that functional physicians and longevity physicians,
7:38
regenerative physicians, have gotten very,
7:39
very comfortable with pharmacies that are very meticulous in the way they
7:44
put things together. For example,
7:46
combining ~ T three thyroid with T four thyroid,
7:49
things like that. There's skill that's involved with this,
7:52
and all not all compounding pharmacies are the same,
7:55
but you can go in and you can actually
7:58
think about it this way that I'm getting exactly what I need.
8:00
And th even though it's an FDA approved drug,
8:03
it may not be FDA approved in this format.
8:05
But the safety profile that we've experienced for people is that it's it's actually
8:10
very safe. So I don't know what your what your rate of complaints might
8:14
be in terms of, you know, reactions or something like that,
8:17
but I suspect it's not very high at all.
8:19
It's not and most of the time it's usually patients more of a sensitivity
8:24
or didn't follow directions, something along those lines is what we see.
8:28
But as far as the product itself,
8:31
no.
8:32
So many times what people are reacting to also,
8:35
~ either in a over the counter C V S Walgreens kind of scenario,
8:40
or even in a compounding pharmacy,
8:42
is that they may there may be a carrier molecule.
8:44
There may be something else that's that's not the active ingredient that they're
8:48
reacting to. And you know, if all you had available to you
8:51
was a traditional pharmacy, you'd kind of be stuck.
8:54
Because that's how it comes. But you can then go to a compounding pharmacy,
8:58
say, I like, I need this, but I can't get along with a carrier.
9:01
Can you put it with a different carrier?
9:03
Right. Now all of a sudden, now they can tolerate it.
9:06
Now they can actually get what it is they came to get,
9:09
right? So that's kind of the beauty of it.
9:10
Absolutely. That's what we see in our line at our five three A is
9:14
we do have patients that they just can't tolerate what's available commercially,
9:18
whether it be a carrier, a stabilizer,
9:20
preservative, whatever it is. And so they're like,
9:22
This is my last chance. Can you help me?
9:25
And of course, you know, we'll do everything we can to help our patients.
9:28
And that's why, you know, we're able to to compound it for them so that they're able
9:32
to get the the treatment they need.
9:34
Mm-hmm. And the the pharmacies themselves are regulated by the state pharmacy boards
9:40
and also by the FDA, if I'm not mistaken,
9:43
right? So even though the actual compounded drug may not be FDA approved
9:48
in that particular configuration,
9:50
the pharmacy itself has to be FDA approved and comply with all
9:54
the state pharmacy laws and all this kind of thing.
9:56
So there are many, many different safeguards,
9:59
if you will, from the consumer's perspective.
10:01
To make sure that they're getting what they say they're getting,
10:04
that the pharmacy says they're getting,
10:05
and that things are being handled in a very safe manner.
10:08
So
10:09
That that's where like the states will have label requirements,
10:12
the FDA will have label label requirements,
10:14
testing requirements, and then there's obviously a list that the
10:18
FDA puts together of ingredients we can even use.
10:21
Yeah, exactly. So that kind of covers a little bit of the five three A.
10:25
So it's gonna look kind of like a pharmacy you've always always seen.
10:27
And then compounding pharmacies sometimes will mail things to your home
10:31
or or that kind of thing, which is kind of an added convenience.
10:34
You'll still need a physician to prescribe it for you,
10:36
somebody that's facile with how to write that prescription,
10:39
what goes into it, etcetera. So you have that.
10:42
And then there's the five three B.
10:44
Which is a little bit of a different animal.
10:45
And you talked about Josh that you've got a couple of those and they
10:48
can make larger quantities of things.
10:51
And why have a five three B in contrast to a five three A?
10:55
Sure.
10:56
There's couple main large scale differences.
10:58
USP governs 503A's, the FDA governs 503.
11:04
US pharmacology standards I would say that kind of set the regulatory compliance
11:09
for ~ compounding. Whereas C G and P,
11:12
which is current good manufacturing processes,
11:14
is what governs a five hundred three B's ability to compound and those
11:17
are the those are the rules we have to follow to make sure anything compounded
11:21
at a B is C G and P versus A has a little bit lower
11:25
Which is the same requirements that pharmaceutical companies have to have to go to.
11:30
Five O three B is like a pharmaceutical company in a sense.
11:33
They have to follow the same guidelines that the FDA sets for those companies
11:37
as well. Whereas on the five O three A side,
11:40
you're governed more by the states.
11:42
FDA does have oversight and they follow most states are adopting
11:47
~ compounding regulations, especially with the big GLP one compounding.
11:52
So
11:53
We're starting to see kind of a shift in regulatory to ensure patient safety.
11:57
Yeah, and it's US pharmacopia,
11:59
I think, is what USP stands for,
12:00
but that's a state regulation essentially of how they govern 503As.
12:04
So 503B is FDA governed, FDA licensed,
12:08
frequent FDA audits, or an A, it's less frequent FDA audits.
12:12
~ so as a B we do state and FDA audits.
12:15
Larger batch sizes because we are able to sell without a prescription directly
12:20
to a clinic.
12:21
That's where the CGMP guidelines for manufacturing comes in.
12:24
We also have a different set of ingredients we can compound with than a 503A.
12:29
And then that's our larger batch sizes.
12:30
It's it's much more large scale manufacturing.
12:33
And then our report card essentially from the FDA is public.
12:37
~
12:37
So when you
12:38
say when you say that from from a five three B that you can sell directly
12:42
to the public without a prescription,
12:43
does that mean that you're bypassing a prescription or people can just walk
12:49
in and say, Hey, want testosterone?
12:50
or what what is that? How does that be a
12:52
licensed
12:53
clinic with a licensed medical director on file,
12:55
we would sh be were able to ship to a clinic for use in the office.
13:00
You're
13:00
purchasing it for office use and then from there the clinic can determine
13:04
if they're going to administer it in the office or dispense it to
13:08
the patient via prescription from their office.
13:11
And that and that's that's also where we're allowed to sell directly to a pharmacy.
13:15
Crowdsourcing and that pharmacy can hold our product as inventory like they would
13:20
a generic drug and then fill trips with our inventory.
13:23
and then the second big difference between a five three B would be
13:27
the shortage list of products that are on FDA shortage,
13:30
meaning a brand new manufacturer,
13:33
generic manufacturer can't keep up with the demand.
13:35
You can then fill the gap by making those products as a five three B.
13:39
Yeah, and this became very evident with the whole GLP one story,
13:43
right? Things got exceeded demand or a demand exceeded capacity.
13:47
And so then all of a sudden the compounding pharmacies were able
13:51
to manufacture the five O three Bs and the Five O three A's were able to dispense.
13:55
So and then the interesting thing is that's a little bit of an elastic situation,
14:00
right? Because you can have a shortage,
14:02
it can last for three months, and then the shortage goes away,
14:05
and now the pharmacy is no longer able to make that exact same
14:09
drug. That is one thing to understand is that the compounding pharmacy can't make
14:14
exactly what the manufacturer is making,
14:16
right? And I believe that's true for both the A's and the B's.
14:19
Right.
14:20
You can't make a commercial
14:21
~
14:22
Over under a ten percent difference for to be considered non-commercially available.
14:27
Okay. So it has to be non commercially available,
14:30
which means it's gonna differ by ten percent up or down.
14:33
At least, yeah, exactly. Basically,
14:34
yeah. Okay, just so the audience understands how this all works a little bit.
14:38
Cause I I think it's everybody's heard about this,
14:40
but I I think it's been confusing for people at the same time.
14:43
Yeah.
14:44
Then a a lot of what you see too with Big Pharma is they group compounding together,
14:48
which they both serve such a unique purpose from customized medication from
14:52
a 503A to large scale manufacturing,
14:55
shortage and or clinic use, office use.
14:58
And like they are two different facilities licensed differently,
15:01
but it is very common for them to be branded the same.
15:04
So I appreciate you kind of letting us explain that.
15:07
Yep.
15:07
Yeah.
15:08
And then what about research molecules and things like that?
15:10
So if there are research trials and things and you don't have
15:14
an FDA approved medication, pharma could basically supply
15:20
a not yet FDA approved drug into a clinical trial.
15:23
And then it's also possible for compounding pharmacies to get involved
15:27
in clinical trials where somebody has devised a particular combination of
15:34
medications that could be FDA approved or maybe not FDA approved
15:38
and then bring those forward inside of a clinical trial.
15:40
Is that part of what you do as well?
15:43
So we don't actively do that. What I believe you're referring to is an ANDA.
15:46
So it's an abbreviated new drug application where we'd be able to help either
15:50
a brand of manufacturer or big pharma kind of create that drug for trials.
15:55
We are not involved in that currently,
15:56
but there's definitely manufacturers that do aid in that.
16:00
It's just a different approval process and different drug application.
16:04
We're only making drugs that are on a list of ingredients for bulk's list
16:08
or shortage.
16:09
Okay, fair enough. And then talk to us a little bit about licensure
16:14
and interstate commerce and things like that,
16:16
right? Because this is a big deal.
16:18
Your license, let's say you're licensed in Florida.
16:20
I don't really know where your licensures extend to,
16:22
but let's say you're only licensed in Florida,
16:24
just as a matter of illustration.
16:26
Then if a doctor saw a person from Georgia in Florida and wrote
16:31
a prescription and they went back to Georgia and wanted to get that filled,
16:35
is that possible? You can send it to them in Georgia or
16:38
Explain to people how that works,
16:40
right?
16:40
Yeah.
16:41
So depending on ~ the states that the pharmacy is licensed in is the states they
16:45
can ship to. You're right. Your state commerce is a big thing in the pharmacy world,
16:50
whether it's compounding specialty.
16:51
So the pharmacies have to be licensed in that state and there's certain requirements
16:56
for the pharmacies, again, depending on their specialty in order to ship
17:00
to those states. So for us, we're able to ship to 49 states.
17:05
including Puerto Rico, and then we're able to service patients in
17:09
all of those states and providers.
17:11
Okay. Which state did you leave out?
17:14
California. Yeah, for now. We do have them scheduled to come to
17:17
our Wesley five three B at the end of this year,
17:20
Q four. Much information as they kinda give you.
17:23
but so the easy way to think of it as well is licensure like our state licensure,
17:28
our medication needs to only be in those states.
17:31
Mm-hmm. Got it. Okay. So that's helpful for people to hear about that because
17:34
sometimes people get caught out with,
17:36
you know, I I got this prescription when I was in Florida,
17:39
you know, I got it filled there by the doctor,
17:41
but now I want to get more of it.
17:42
And now I can't get it because I'm in Georgia.
17:44
Right. And so yeah, important for you to understand the restrictions that
17:48
are around that. So typically if somebody and you're licensed
17:51
in Forty United States, but not in California.
17:53
So let's say you had a client that saw you in Florida,
17:55
a Florida doctor, they got the prescription there,
17:58
but they went home to California,
17:59
they want to get more of it.
18:00
Now the the pickle that they're in,
18:02
so to speak, is to find a compound pharmacy in California or one that's licensed
18:07
in California that can actually provide that to them.
18:11
Correct. And we run into that quite often just because,
18:15
you know, the way people travel,
18:16
they have multiple homes. Obviously a lot of patients come to Florida for vacation.
18:21
They might see someone here, get the meds.
18:23
So yeah, we try to do our best to kind of navigate through that to
18:27
see what options they might have.
18:28
Yeah. And then let's talk a little bit about peptides because,
18:31
you know, everybody's been aware that,
18:33
you know, the peptide world kind of got clamped down on by the FDA and
18:37
and then they started going after some of the research only
18:40
use peptide manufacturers, which is a little bit of a a mixed bag,
18:44
right? I mean, there are people out there that are selling garbage
18:47
and there are people out there that that probably selling high quality stuff.
18:50
And then with the peptides now,
18:52
the FDA has
18:53
I think recommended nobody's approved anything,
18:56
but what I understand they've recommended I think about eight different peptides
18:59
for consideration for some sort of approval.
19:03
Do you wanna walk us through kind of where where the FDA is with that?
19:06
Yeah, absolutely. So ~ a couple weeks ago the FDA had
19:10
a pharmacy compounding committee come together and look at eight different peptides.
19:15
Out of the eight, if I'm not mistaken,
19:18
seven of them were approved, or the committee said to the FDA,
19:22
these are ones that we feel need to be added to the 503A Bulk's list.
19:27
Now from there, the FDA still has to make their determination on if they want
19:32
to approve them and put them on the list.
19:35
for pharmacies, 503A pharmacies to compound or not.
19:39
Really nothing has been decided by the FDA.
19:42
We are just moving, in a sense,
19:44
one step closer and the conversation is obviously opening up to allow these
19:49
to be compounded. So we're getting there,
19:51
but we're about halfway there.
19:53
We're we're not to the finish line.
19:55
And what's the timeline on that for people to just I mean,
19:58
people are curious, right? And because some people are very adamant,
20:02
I don't want to get it from just,
20:03
you know, offshore or research place or something like that.
20:07
I'm really waiting for a compounding pharmacy.
20:08
Do we have any sense of the timing on this when the FTA's gonna meet?
20:12
Well, we're talking about the FDA.
20:14
So
20:15
Yeah, right.
20:16
they still have to go through a comment period,
20:19
which is typically anywhere from thirty to sixty days,
20:21
and then from there they could have thirty to sixty days to determine.
20:25
So we are hopeful early fall we might hear something.
20:29
But again, a lot of things get pushed back,
20:31
plans change, meetings change.
20:33
So we don't have a definite this is when they're supposed to make the decision.
20:37
Yeah. the the rule of thumb right now is there's open comment period.
20:42
So I think at the earliest it would be sixty days from the recommendation.
20:45
But we're hopeful we're kind of keeping our ear to the wall to hear what happens.
20:49
And then honestly more intriguing for us is if this goes on an A list,
20:54
do they also put it on a five three B list?
20:56
~ we don't have any clarification there either.
20:59
But I will say though, just for the PCAT committee,
21:01
if anyone didn't listen, there were three things that were constantly brought
21:05
up by the FDA. One was
21:07
Lack of FDA oversight on 503As,
21:10
which a 503B has direct FDA oversight.
21:13
lack of ~ adverse event reporting from an A,
21:17
which are 503Bs required. And then also CGMP manufacturing these products,
21:21
which is a requirement from a 503B.
21:23
So a lot of the statements that the FDA made did kind of steer us into more 503B
21:28
compounding of these. but again,
21:30
we we have to kind of wait and see.
21:32
Got it. So for the ~ for the consumer here,
21:35
we're kind of in a holding pattern.
21:36
It sounds like we may learn something about access to these seven different peptides
21:41
through compounding pharmacies,
21:43
you know, maybe later this year.
21:44
It sounds like we're gonna know something by twenty twenty six.
21:46
So if you're kind of sitting on the fence about whether or not to use peptides,
21:50
these particular ones, you can think about it that way.
21:53
What are some of the other issues that you think people need
21:56
to understand about compounding pharmacies and kind of maybe things that even
22:00
distinguish you from
22:02
From other compounding pharmacies.
22:03
Yeah.
22:04
Can
22:04
answer that in two parts. Do you want to speak directly to the peptides first
22:07
and kind of what is in the market for that?
22:10
And then I'll go and just generically ~ what I think is important
22:14
for picking a compounding pharmacy,
22:16
whether A or B. When it comes to these peptides as well,
22:19
so there's no USP monograph. That was a common topic brought up of what is BPC?
22:24
What is MOTC? So I from an from our perspective,
22:27
we have to vet and audit every supplier of our raw ingredients.
22:32
They're called
22:33
Active pharmaceutical ingredients,
22:35
which is API for short, and their powder forms of these ingredients.
22:38
We have to audit that supplier and vet that supplier.
22:40
So and those suppliers that we use have to be FDA registered but also FDA audited.
22:45
So we have found a lot of peptides and just overall ingredients that
22:49
we make through these manufacturers.
22:51
And I think it starts there. It starts where you get your
22:53
raw ingredients because then from there the pharmacies can compound those products
22:58
aseptically in a sterile environment and have a finished good that is sterile.
23:02
I think that's really important to note is is with these peptides
23:05
or just in products in raw ingredients in general is where
23:08
are these ingredients coming from.
23:09
And from a 503B perspective, there's a lot of hoops,
23:12
I would say, regulatory compliance checks that we go through to make sure that
23:16
raw ingredients are safe to use and we do a lot of raw ingredient testing before
23:20
using. And then I would say with these peptides specifically,
23:24
what compounding pharmacies required to do is test for potency.
23:28
Amongst other things, we test for assay pH colors.
23:30
So from a 503B, you as a prescriber will feel more confident
23:35
in your prescription because you'll know that that that finished product
23:38
is on between ninety and a hundred and ten percent potency.
23:41
So they're not over-injecting a highly potent product or under injecting where it's
23:46
not effective an an a a lower potency product.
23:50
So I think that's really relevant.
23:51
When it comes to picking your compounder,
23:53
503Bs, their report card is published online.
23:56
You can go to the FDA registry and see their last audit.
23:58
I think that's really relevant in as a prescriber or even a patient
24:02
of where your product's coming from.
24:03
I think that'd be really, really beneficial to know.
24:05
Those are a few things. I mean,
24:06
I can dive into more if you'd like,
24:08
but I don't want to get too gr too granular.
24:11
Yeah. No, I think that's helpful.
24:12
I think it's helpful for people to know that they can go look at
24:15
a public disclosure report card really on what's how the five three B is doing,
24:20
right? And whether they're being compliant.
24:22
I do know that compounding pharmacies not all are equal,
24:25
right? In terms of their rigor and precision and things like that.
24:29
And so it's very important if you're listening to this that you work with
24:32
a pharmacy that maybe your physician's vetted or you vetted or you know,
24:37
you've you figure out who's really
24:39
Providing the high quality things in your area,
24:41
~ so you can access those.
24:44
One of the biggest things is at least from what we hear on the phone and
24:47
we talk to patients and providers,
24:49
is they just really don't know what to look for.
24:51
So yes, being able to see the 503Bs,
24:54
their report card, understanding what infractions they might have or
24:58
not have is very important. And then just calling the pharmacy just to
25:03
see if their staff knows, like,
25:05
hey, we do have a quality team,
25:07
we do do testing, we do have a pharmacist available to talk if needed
25:11
to either providers or patients.
25:13
I think is a big thing that a lot of people need to understand.
25:16
If you're gonna get that product from that pharmacy,
25:18
you should be able to talk to someone about it at that pharmacy.
25:21
Yeah, we found it to be, you know,
25:23
extremely helpful. I mean, we use compounding pharmacies all the time
25:27
for various things. And I think if you're in this space of or stepping into this
25:32
space of functional medicine or longevity medicine,
25:34
regenerative medicine, and you're not familiar with compounding pharmacies,
25:37
this is a very important thing for you to get familiar with because you're gonna
25:41
want to access that to get things that you just can't get off the shelf,
25:45
quite honestly. Absolutely. Okay,
25:47
well, I appreciate you guys coming on.
25:49
Were there anything else that you wanted to cover?
25:51
For the audience.
25:52
I don't have anything off the top of my head.
25:53
If there's any questions or follow ups,
25:55
you can always email us and we can answer those questions as well.
25:58
If you are interested in Olympia pharmaceuticals or Wesley pharmaceuticals,
26:02
we have ask the pharmacist at olympia pharmacy dot com for any dosing questions,
26:06
product questions, anything you can think of.
26:09
And then all of our phones ring,
26:11
so we are very proud that we'll answer any call that comes in,
26:14
whether sales, accounting, clinical pharmacy.
26:17
So we'd be happy to help. And steering the right direction,
26:19
we don't make everything.
26:21
We have such great connections in this industry and we definitely will
26:23
see her in the right way because at the end of the day we want to help patients
26:26
and we definitely want to help prescribers help their patients.
26:29
Mm-hmm. Yeah. And you're located in Orlando,
26:31
Florida, just so everybody knows.
26:33
So when they go by Disney World or whatever,
26:35
they can stop
26:36
We can see Harry Potter's castle from our office.
26:39
it's a lot of fireworks going on.
26:40
So
26:41
Yeah, for sure.
26:42
Great. Well, thanks so much for joining us.
26:44
Really ~ I think it's been clarifying for the people listening.
26:47
So thank you for the
26:49
Doctor
26:49
for having us.
26:50
Absolutely. Thank you guys. How do we live young for a lifetime?
26:53
How do we make 100 the new 30?
26:55
The answers are out there, and we send them to you every episode.
27:00
Make sure you're subscribed. Check out more episodes right here.
27:04
And follow us on social media so you never miss a breakthrough.
27:08
Thanks for listening.